secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001562762-23-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q4 2022 adjusted EPS $5.39 (+2.7% YoY); guides 2023 adjusted EPS $20.75-$21.10
--------------------------------------------------------------------------------

- Consolidated revenue $547M (+1.0% YoY); GAAP diluted EPS $4.13; adjusted diluted EPS $5.39.
- VITAS net patient revenue $308M (-2.5%); ADC 17,434 (-2.8%); admissions -8.7%; adjusted EBITDA margin 19.8% (-189bps).
- Roto-Rooter revenue $239M (+6.1%); adjusted EBITDA $69.3M (+11.4%); margin 29.0% (+138bps).
- 2023 guidance: VITAS revenue +6-7%, ADC +3.5-4%; Roto-Rooter revenue +5-5.5%; adjusted EPS $20.75-$21.10.
- Share repurchases: 25,000 shares for $13.0M in Q4; $88M remaining authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276223000053/0001562762-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276223000053/che-20230223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer